Patents Assigned to Discoverx
  • Publication number: 20240018509
    Abstract: The present invention provides methods and kits for identifying interactions between a test compound and a phage-displayed polypeptide, wherein the phage-displayed polypeptide is not a kinase but a protein domain of interest, such as an SH2 domain of interest. The protein domain of interest is displayed on the phage, and the interactions are evaluated in the presence of a reference ligand and in the presence and absence of the test compound.
    Type: Application
    Filed: July 15, 2023
    Publication date: January 18, 2024
    Applicant: Eurofins DiscoverX Corporation
    Inventors: Jean Alexandre Bernatchez, Daniel Kelly Treiber, Ksenya Cohen Katsenelson
  • Publication number: 20200308591
    Abstract: Provided are methods of assessing activity of a promoter region. The methods include culturing a cell including a nucleic acid, the nucleic acid including a region that encodes an enzyme donor (ED) operably coupled to a promoter region, under conditions in which the ED is expressed when the promoter region is active. The methods further include contacting the ED, if expressed, with an enzyme acceptor (EA) to form ED-EA complexes having enzymatic activity. The methods further include detecting the level of the enzymatic activity to assess activity of the promoter region. Activity of the promoter region may be indicative, and therefore may be used to assess, the activity of a cellular signaling pathway of interest and/or of endogenous or exogenous (e.g., introduced) transcription factors of interest. Cells, compositions, and kits that find use, e.g., in practicing the methods of the present disclosure, are also provided.
    Type: Application
    Filed: March 26, 2020
    Publication date: October 1, 2020
    Applicant: Eurofins DiscoverX Corporation
    Inventors: Paul Shapiro, Venkatesh Chari, Jennifer Lin-Jones, Jane Lamerdin
  • Patent number: 10641776
    Abstract: Disclosed are methods for detecting and quantitatively measuring a binding property of a compound to a target macromolecule, wherein the target macromolecule is subject to denaturation and is linked to a labeling peptide, such as a short enzyme fragment. The method uses a fluid mixture comprising (i) a chimeric molecule comprising a target macromolecule linked to the labeling peptide, wherein the target macromolecule may be a chimeric protein expressed by and within an intact viable cell and (ii) a compound being measured for binding to the target macromolecule, wherein said target macromolecule is subject to denaturation. After allowing for binding of the compound (e.g. a small molecule inhibitor of the target macromolecule), one detects a signal from the labeling peptide, such as by enzyme fragment complementation.
    Type: Grant
    Filed: February 16, 2018
    Date of Patent: May 5, 2020
    Assignee: Eurofins Discoverx Corporation
    Inventors: Daniel K. Treiber, Elena Menichelli
  • Patent number: 10324092
    Abstract: Provided herein are nucleic acid tags that are linked to, or capable of linking to, a protein of interest. In particular, the nucleic acid tags are oligonucleotides comprising a reporter function and a protein tagging function. Also provided herein, are nucleic acid tag compositions, kits and methods of use thereof.
    Type: Grant
    Filed: July 28, 2015
    Date of Patent: June 18, 2019
    Assignee: Eurofins DiscoverX Corporation
    Inventors: Pietro Ciceri, Jeremy Hunt, Jean-Michel A. Lelias, Mike Morrison, Daniel K. Treiber, Lisa Wodicka
  • Patent number: 10240255
    Abstract: Methods and systems for evaluating biological dataset profiles relating to toxic agents including candidate pharmaceuticals, environmental agents, biowarfare and chemical warfare agents are provided, where datasets comprising information for multiple cellular parameters are compared and identified, and used in the evaluation of candidate agents.
    Type: Grant
    Filed: April 21, 2014
    Date of Patent: March 26, 2019
    Assignee: EUROFINS DISCOVERX CORPORATION
    Inventor: Ellen L. Berg
  • Patent number: 10018621
    Abstract: A method of screening biologically active agent based on the analysis of complex biological responses in culture. Methods for selecting cells and culture conditions for such screens are provided, as well as the identification of an optimized set of discrete parameters to be measured, and the use of biomap analysis for rapid identification and characterization of drug candidates, genetic sequences acting pathways, and the like. A feature of the invention is simultaneous screening of a large number of cellular pathways, and the rapid identification of compounds that cause cellular responses.
    Type: Grant
    Filed: June 13, 2013
    Date of Patent: July 10, 2018
    Assignee: Eurofins Discoverx Corporation
    Inventors: Ellen L. Berg, Eugene C. Butcher, Jennifer Melrose
  • Patent number: 9734282
    Abstract: Methods and systems for evaluating biological dataset profiles relating to inflammatory cardiovascular conditions are provided, where datasets comprising information for multiple cellular parameters are compared and identified, and used in the evaluation of candidate pharmacologic agents for suitability as therapeutic agents.
    Type: Grant
    Filed: March 28, 2006
    Date of Patent: August 15, 2017
    Assignee: DISCOVERX CORPORATION
    Inventors: Jennifer Melrose, Elen Rosler, Melissa Fischer, Sylvie Privat, Eric J. Kunkel, Ellen Berg
  • Patent number: 9618516
    Abstract: Disclosed are methods for detecting and quantitatively measuring a binding property of a compound to a target macromolecule, wherein the target macromolecule is subject to denaturation and is linked to a labeling peptide, such as a short enzyme fragment. The method uses a fluid mixture comprising (i) a chimeric molecule comprising a target macromolecule linked to the labeling peptide and (ii) a compound being measured for binding to the target macromolecule, wherein said target macromolecule is subject to denaturation. After allowing for binding of the compound (e.g. a small molecule inhibitor of the target macromolecule), one detects a signal from the labeling peptide, such as by enzyme fragment complementation. This signal indicates a differential between denatured and non-denatured target macromolecules and thereby indicates a differential between target macromolecules not bound to the compound and target macromolecules bound to the compound, respectively.
    Type: Grant
    Filed: August 19, 2015
    Date of Patent: April 11, 2017
    Assignee: DISCOVERX CORPORATION
    Inventors: Daniel K. Treiber, Elena Menichelli
  • Patent number: 9388449
    Abstract: Methods and materials are disclosed for use in an enzyme fragment complementation assay using complementary fragments of ?-galactosidase to study the trafficking of proteins in a cell. Compounds that bind to a target peptide have been found to affect protein folding and therefore trafficking. ?-Galactosidase fragments, an enzyme donor (ED) and an enzyme acceptor (EA), are fused to a target peptide and to an intracellular compartment protein, wherein the compartment is involved in intracellular trafficking. Contacting the cell with a compound that binds to the target peptide results in enhanced movement of the protein through the cellular trafficking pathway comprised of the endoplasmic reticulum, Golgi apparatus, the plasma membrane, endosomes, etc. Using this approach, compounds that bind to a target peptide and alter its ability to traffic through the normal cellular pathway can be readily detected.
    Type: Grant
    Filed: October 21, 2013
    Date of Patent: July 12, 2016
    Assignee: DISCOVERX CORPORATION
    Inventors: Thomas S. Wehrman, Daniel Bassoni, William Raab
  • Patent number: 9267165
    Abstract: The invention provides methods for determining the interactions between phage-displayed proteins and test molecules. The phage-displayed proteins are contacted with a reference moiety in the presence and absence of a test molecule; the behavior of the phage-displayed proteins as a function of concentration of the test molecule permits calculation of the binding affinity of the phage-displayed protein for the test molecule.
    Type: Grant
    Filed: August 23, 2007
    Date of Patent: February 23, 2016
    Assignee: DiscoveRx Corporation
    Inventors: David J. Lockhart, Patrick Parvis Zarrinkar, Daniel Kelly Treiber
  • Patent number: 9110054
    Abstract: Provided herein are nucleic acid tags that are linked to, or capable of linking to, a protein of interest. In particular, the nucleic acid tags are oligonucleotides comprising a reporter function and a protein tagging function. Also provided herein, are nucleic acid tag compositions, kits and methods of use thereof.
    Type: Grant
    Filed: June 29, 2007
    Date of Patent: August 18, 2015
    Assignee: DiscoveRx Corporation
    Inventors: Pietro Ciceri, Jeremy Hunt, Jean-Michel A. Lelias, Mike Morrison, Daniel Treiber, Lisa Wodicka
  • Patent number: 8945853
    Abstract: Methods and compositions are provided to measure the binding of a test compound to a target peptide by measuring the effect of the compound on the abundance of the target peptide inside a cell. The target peptide may bind the test compound at an active site or an allosteric site, and it has been found that such binding may stabilize the target peptide against cellular degradation. The target peptide will preferably comprise a destabilizing mutation which shortens the half life of the target peptide within the cell, typically a mammalian cell. Test compounds, including small molecules, have been found to stabilize target peptides. Also provided are systems and kits for use in practicing the methods.
    Type: Grant
    Filed: February 5, 2013
    Date of Patent: February 3, 2015
    Assignee: DiscoveRx Corporation
    Inventors: William Raab, Thomas S. Wehrman
  • Publication number: 20140315731
    Abstract: Methods and systems for evaluating biological dataset profiles relating to toxic agents including candidate pharmaceuticals, environmental agents, biowarfare and chemical warfare agents are provided, where datasets comprising information for multiple cellular parameters are compared and identified, and used in the evaluation of candidate agents.
    Type: Application
    Filed: April 21, 2014
    Publication date: October 23, 2014
    Applicant: DISCOVERX CORPORATION
    Inventor: Ellen L. Berg
  • Patent number: 8865421
    Abstract: Methods and genetic constructs are provided for detecting the binding of nuclear hormone receptors to a coactivator/corepressor. The methods employ enzyme fragment complementation using fragments of ?-galactosidase as the detection system. Cells are transformed to express the large fragment of ?-galactosidase fused to a member of the complex with NHR for initiation of transcription and have it localized in the nucleus and to express the small fragment of ?-galactosidase fused to the nuclear hormone receptor for binding to the member upon stimulation with a ligand.
    Type: Grant
    Filed: June 23, 2009
    Date of Patent: October 21, 2014
    Assignee: DiscoveRx Corporation
    Inventors: Thomas S. Wehrman, Chin Yee Loh, Mahesh Mathrubutham, Keith R. Olson
  • Publication number: 20140288032
    Abstract: Agents that inhibit or prevent restenosis are identified by assaying test agents in a battery of assays to measure the effect of the test agent on cell proliferation, thrombosis, tissue modeling, and inflammation. Treatment for restenosis is provided using compositions of the invention.
    Type: Application
    Filed: March 18, 2014
    Publication date: September 25, 2014
    Applicant: DiscoveRx Corporation
    Inventors: Eric J. Kunkel, Evangelos Hytopoulos, Ivan Plavec
  • Patent number: 8741559
    Abstract: Provided herein are assays useful, for example, for determining the activity of a protein involved in a cellular process. In some embodiments, the activity of the protein is assessed using a nucleic acid tag, and in particular, by detecting the presence of a nucleic acid tag. Such assays can be used, for example, to study the effects of test compounds as modulators, e.g., inhibitors, agonists and antagonists, of protein activity.
    Type: Grant
    Filed: April 23, 2010
    Date of Patent: June 3, 2014
    Assignee: DiscoveRx Corporation
    Inventors: Daniel Kelly Treiber, Warren G. Lewis, Lisa M. Wodicka
  • Patent number: 8718945
    Abstract: Methods and systems for evaluating biological dataset profiles relating to toxic agents including candidate pharmaceuticals, environmental agents, biowarfare and chemical warfare agents are provided, where datasets comprising information for multiple cellular parameters are compared and identified, and used in the evaluation of candidate agents.
    Type: Grant
    Filed: March 28, 2008
    Date of Patent: May 6, 2014
    Assignee: DiscoveRx Corporation
    Inventor: Ellen L. Berg
  • Publication number: 20140045194
    Abstract: Methods and materials are disclosed for use in an enzyme fragment complementation assay using complementary fragments of ?-galactosidase to study the trafficking of proteins in a cell. Compounds that bind to a target peptide have been found to affect protein folding and therefore trafficking. ?-Galactosidase fragments, an enzyme donor (ED) and an enzyme acceptor (EA), are fused to a target peptide and to an intracellular compartment protein, wherein the compartment is involved in intracellular trafficking. Contacting the cell with a compound that binds to the target peptide results in enhanced movement of the protein through the cellular trafficking pathway comprised of the endoplasmic reticulum, Golgi apparatus, the plasma membrane, endosomes, etc. Using this approach, compounds that bind to a target peptide and alter its ability to traffic through the normal cellular pathway can be readily detected.
    Type: Application
    Filed: October 21, 2013
    Publication date: February 13, 2014
    Applicant: DiscoveRx Corporation
    Inventors: Thomas S. Wehrman, Daniel Bassoni, William Raab
  • Patent number: 8569057
    Abstract: Methods and materials are disclosed for use in an enzyme fragment complementation assay using complementary fragments of ?-galactosidase to study the trafficking of proteins in a cell. Compounds that bind to a target peptide have been found to affect protein folding and therefore trafficking. ?-Galactosidase fragments, an enzyme donor (ED) and an enzyme acceptor (EA), are fused to a target peptide and to an intracellular compartment protein, wherein the compartment is involved in intracellular trafficking. Contacting the cell with a compound that binds to the target peptide results in enhanced movement of the protein through the cellular trafficking pathway comprised of the endoplasmic reticulum, Golgi apparatus, the plasma membrane, endosomes, etc. Using this approach, compounds that bind to a target peptide and alter its ability to traffic through the normal cellular pathway can be readily detected.
    Type: Grant
    Filed: June 22, 2012
    Date of Patent: October 29, 2013
    Assignee: DiscoveRx Corporation
    Inventors: Thomas S. Wehrman, Daniel Bassoni, William Raab
  • Publication number: 20130203067
    Abstract: Methods and compositions are provided to measure the binding of a test compound to a target peptide by measuring the effect of the compound on the abundance of the target peptide inside a cell. The target peptide may bind the test compound at an active site or an allosteric site, and it has been found that such binding may stabilize the target peptide against cellular degradation. The target peptide will preferably comprise a destabilizing mutation which shortens the half life of the target peptide within the cell, typically a mammalian cell. Test compounds, including small molecules, have been found to stabilize target peptides. Also provided are systems and kits for use in practicing the methods.
    Type: Application
    Filed: February 5, 2013
    Publication date: August 8, 2013
    Applicant: DISCOVERX CORPORATION
    Inventor: DiscoveRx Corporation